Anupam Rasayan Reports Robust FY26 Growth, Acquires Pharma Firm

Anupam Rasayan India Ltd's revenue from operations soared by 64.6% to ₹2,384 crore in FY26, compared to ₹1,448 crore in FY25. EBITDA grew 31.8% to ₹543 crore, and Profit After Tax increased by 38.8% to ₹222 crore.

Reader Takeaway: Strong revenue growth and portfolio diversification are positives, while pharma acquisition integration poses a watch point.

What just happened

Anupam Rasayan India Ltd announced its financial results for the fiscal year ended March 31, 2026 (FY26). The company reported a substantial 64.6% year-on-year increase in revenue from operations, reaching ₹2,384 crore.

Profitability also saw a significant uplift, with EBITDA rising by 31.8% to ₹543 crore and Profit After Tax (PAT) growing by 38.8% to ₹222 crore. The company also disclosed its definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma Ltd, with an open offer for an additional 26%.

Why this matters

The robust financial performance demonstrates Anupam Rasayan's strong execution and scaling of operations. The acquisition of Bliss GVS Pharma signals a strategic move to create an integrated pharmaceutical Contract Development and Manufacturing Organization (CDMO) platform, diversifying its revenue base beyond agrochemicals.

The backstory

Anupam Rasayan has been focused on diversifying its business. Its revenue contribution from agrochemicals has decreased from 76% in FY22 to 55% in FY26, indicating a successful shift towards high-performance materials, pharmaceuticals, and other segments. The company plans to fund the Bliss GVS Pharma acquisition through approximately ₹300 crore in non-convertible debentures (NCDs) and quasi-equity instruments.

What changes now

The acquisition of Bliss GVS Pharma, once completed, will enable Anupam Rasayan to offer a more comprehensive pharmaceutical value chain, from Key Starting Materials (KSM) to finished dosage forms. Management expects a pro forma revenue exceeding ₹4,000 crore and envisions Bliss GVS Pharma operating independently, leveraging synergies.

Risks to watch

While the acquisition offers strategic advantages, the integration process, which management estimates will take 6-18 months, presents a key risk. The success of this integration will be crucial for realizing projected synergies. Additionally, despite diversification efforts, the company still derives 55% of its revenue from the agrochemical segment, making it susceptible to cycles within that industry.

Peer comparison

(No direct peer comparison data was provided in the filing.)

Context metrics (time-bound)

• FY26 Revenue: ₹2,384 crore (up 64.6% YoY)
• FY26 EBITDA: ₹543 crore (up 31.8% YoY)
• FY26 Profit After Tax: ₹222 crore (up 38.8% YoY)
• FY26 Operational Cash Flow: ₹334 crore
• Agrochemical revenue contribution: 55% in FY26 (down from 76% in FY22)

What to track next

Investors will be closely watching the successful integration of Bliss GVS Pharma and its contribution to Anupam Rasayan's revenue and profitability. Management's guidance for a 20%-30% CAGR growth over the next 3-5 years will be a key metric to monitor.